Skip to main content
SPRO logo

SPRO · Spero Therapeutics, Inc.

$1.21 +0.05 (+4.31%)
Market Cap
$67.17M
Shares
57.90M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Esther Rajavelu $2,061,496
Satyavrat Shukla $2,025,178
Tim Keutzer $1,440,820
Fiscal 2024
Executive Total
Satyavrat Shukla $1,953,237
Tim Keutzer $1,033,450
Esther Rajavelu $856,479
Fiscal 2023
Executive Total
Ankit Mahadevia $2,385,905
Satyavrat Shukla $2,024,648
Tamara Joseph $1,455,126
Timothy Keutzer $1,438,569
Tim Keutzer $1,438,569
Esther Rajavelu $458,054
Fiscal 2022
Executive Total
Ankit Mahadevia $4,239,705
Satyavrat Shukla $1,673,070
Tamara Joseph $1,625,358
Timothy Keutzer $1,585,037
Fiscal 2021
Executive Total
Ankit Mahadevia $4,875,045
Satyavrat Shukla $2,228,271
Cristina Larkin $1,903,930
Tamara Joseph $980,075
Fiscal 2020
Executive Total
Ankit Mahadevia $2,120,788
David Melnick $999,913
Christina Larkin $991,962
Cristina Larkin $991,962
Satyavrat Shukla
Fiscal 2019
Executive Total
Ankit Mahadevia $1,789,374
Christina Larkin $947,983
David Melnick $939,789
Fiscal 2018
Executive Total
David Melnick $1,634,361
Ankit Mahadevia $721,324
Christina Larkin $533,799
Key facts CIK 1701108 CUSIP 84833T103 13F (30d) 6 filings 6 filers Visit website Investor relations